HEMO-CAR-T

N/A

Report date: 2025/01/26 15:53:37

Base Information

Drug NameHEMO-CAR-T

Drug Alias Nameanti-FLT3 CAR T-cell therapy (Hemogenyx)HEMO-CAR-T

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitors

TargetsTyrosine-protein kinase receptor FLT3

Therapy Area/IndicationsLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesHemogenyx Pharmaceuticals PLC

China Registration ClassN/A

Develop Information

Active CompaniesHemogenyx Pharmaceuticals PLC

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A